Endocrine Toxicities of Antineoplastic Therapy
In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...]
Main Authors: | Giulia Puliani, Marialuisa Appetecchia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/2/294 |
Similar Items
-
Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic
by: Agnese Barnabei, et al.
Published: (2022-01-01) -
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
by: Marta Bianchini, et al.
Published: (2021-10-01) -
Design and Synthesis of Organic Molecules as Antineoplastic Agents
by: Carla Boga, et al.
Published: (2020-06-01) -
Editorial for the Special Issue “New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies”
by: Carlos Martínez-Campa, et al.
Published: (2020-06-01) -
Endocrine Disrupting Chemicals: Effects on Endocrine Glands
by: Rosa Lauretta, et al.
Published: (2019-03-01)